Ruxience is not covered on the Reformulary. Reformulary Group has selected specific rituximab biosimilar to be covered: RIXIMYO, manufactured by Sandoz, a division of Novartis Canada. RIXIMYO is considered a preferred rituximab biosimilar as it offers the same clinical value at a lower net cost to the plan. RIXIMYO requires Special Authorization.
Ruxience is used to treat
Granulomatosis with Polyangiitis/Microscopic Polyangiitis